Colorectal Cancer

Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

The combination of cabozantinib and nivolumab showed 16-week disease control in microsatellite stable colorectal cancer.

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab for adult patients with KRAS G12C–mutated metastatic colorectal cancer.

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Marwan G. Fakih, MD, discusses response rates with botensilimab plus balstilimab in patients with microsatellite-stable colorectal cancer.

Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer across all lines of therapy.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experience poor clinical outcomes, according to real-world data.

Detectable ctDNA after neoadjuvant chemotherapy was associated with the recommendation for TME in patients with T1-3, N0 low or mid rectal cancer.

A longer-term follow-up analysis showed that adagrasib/cetuximab demonstrated clinically meaningful efficacy in KRAS G12C–mutated advanced CRC.

Updated phase 2 data revealed fruquintinib plus TAS-102 could offer survival benefits in pretreated metastatic colorectal cancer.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Nivolumab plus ipilimumab led to early and sustained PFS benefits vs nivolumab alone across all lines of therapy in patients with dMMR/MSI-H mCRC.

Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.

Trifluridine/tipiracil showed a numerical, but not significant, DFS improvement in all patients with residual disease after curative resection of CRC.

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

ctDNA positivity was associated with worse DFS overall but significantly better DFS with celecoxib vs placebo in stage III resected colon cancer.